First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03852511 |
|
Recruitment Status :
Recruiting
First Posted : February 25, 2019
Last Update Posted : February 7, 2020
|
Sponsor:
PsiOxus Therapeutics Ltd
Information provided by (Responsible Party):
PsiOxus Therapeutics Ltd
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2021 |
| Estimated Study Completion Date : | June 2021 |